NASDAQ · LMRI

Lumexa Imaging Holdings, Inc.

$11.05 +$0.12 (+1.10%) 1D After hours

Key Metrics

$1.05B
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 1.60
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 18
    From its Feb 18 high, the share price fell 58%.

    Peak close $15.99 on Feb 18; trough close $6.77 on May 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -58%
  • May 13
    The stock moved -23.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 13
  • Mar 26
    The stock moved -29.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 26

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.05B
Enterprise value$1.83B
Shares outstanding96.1M
52-wk range$6.45 – $19.45
Avg volume · 20D838.3K
Net cash −$779.19M
Book value / share$6.24
IndustryServices-Medical Laboratories
ExchangeNASDAQ
About Lumexa Imaging Holdings, Inc.
IPO dateDec 11, 2025
Employees4335

Lumexa Imaging Holdings Inc is a provider of diagnostic imaging services. The company offers a broad range of imaging modalities, including MRI, CT, PET, X-ray, ultrasound, and mammography.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio1.40
Quick ratio
Debt / equity1.38
Debt / EBITDA
Net cash −$779.19M
Working capital$63.96M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings